Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Chongqing Lummy Pharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Chongqing Lummy Pharmaceutical has a total shareholder equity of CN¥2.1B and total debt of CN¥254.5M, which brings its debt-to-equity ratio to 12%. Its total assets and total liabilities are CN¥2.9B and CN¥783.8M respectively.
Anahtar bilgiler
12.0%
Borç/özkaynak oranı
CN¥254.50m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | CN¥921.08m |
| Eşitlik | CN¥2.13b |
| Toplam yükümlülükler | CN¥783.83m |
| Toplam varlıklar | CN¥2.91b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%
Oct 01
What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You
Oct 01Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)
Feb 27Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 300006's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥672.1M).
Uzun Vadeli Yükümlülükler: 300006's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥111.8M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 300006 has more cash than its total debt.
Borcun Azaltılması: 300006's debt to equity ratio has reduced from 56.1% to 12% over the past 5 years.
Borç Kapsamı: 300006's debt is well covered by operating cash flow (78.6%).
Faiz Kapsamı: Insufficient data to determine if 300006's interest payments on its debt are well covered by EBIT.